



The impact of hypertension on clinical outcomes in moyamoya disease: a multicenter, propensity score-matched analysis

Basel Musmar¹ · Joanna M. Roy¹ · Hammam Abdalrazeq¹ · Elias Atallah¹ · Kareem El Naamani² · Ching-Jen Chen³ · Roland Jabre¹ · Hassan Saad⁴ · Jonathan A. Grossberg⁴ · Adam A. Dmytriw^{5,6} · Aman B. Patel⁶ · Mirhojjat Khorasanizadeh⁷ · Christopher S Ogilvy⁷ · Ajith J. Thomas⁸ · Andre Monteiro⁹ · Adnan Siddiqui⁹ · Gustavo M. Cortez¹⁰ · Ricardo A. Hanel¹⁰ · Guilherme Porto¹¹ · Alejandro M. Spiotta¹¹ · Anthony J. Piscopo¹² · David M. Hasan¹³ · Mohammad Ghorbani¹⁴ · Joshua Weinberg¹⁵ · Shahid M. Nimjee¹⁵ · Kimon Bekelis¹⁶ · Mohamed M. Salem¹⁷ · Jan-Karl Burkhardt¹⁷ · Akli Zetchi^{18,19} · Charles Matouk^{18,19} · Brian M. Howard⁴ · Rosalind Lai⁶ · Rose Du⁶ · Rawad Abbas¹ · Georgios S Sioutas¹ · Abdelaziz Amllay¹ · Alfredo Munoz¹ · Nabeel A. Herial¹ · Stavropoula I. Tjoumakaris¹ · Michael Reid Gooch¹ · Robert H. Rosenwasser¹ · Pascal Jabbour¹

Received: 24 July 2024 / Accepted: 3 September 2024
© The Author(s) 2024

Abstract

Background Moyamoya disease (MMD) is a rare cerebrovascular disorder characterized by progressive steno-occlusive changes in the internal carotid arteries, leading to an abnormal vascular network. Hypertension is prevalent among MMD patients, raising concerns about its impact on disease outcomes. This study aims to compare the clinical characteristics and outcomes of MMD patients with and without hypertension.

Methods We conducted a multicenter, retrospective study involving 598 MMD patients who underwent surgical revascularization across 13 academic institutions in North America. Patients were categorized into hypertensive ($n=292$) and non-hypertensive ($n=306$) cohorts. Propensity score matching (PSM) was performed to adjust for baseline differences.

Results The mean age was higher in the hypertension group (46 years vs. 36.8 years, $p < 0.001$). Hypertensive patients had higher rates of diabetes mellitus (45.2% vs. 10.7%, $p < 0.001$) and smoking (48.8% vs. 27.1%, $p < 0.001$). Symptomatic stroke rates were higher in the hypertension group (16% vs. 7.1%; OR: 2.48; 95% CI: 1.39-4.40, $p = 0.002$) before matching. After PSM, there were no significant differences in symptomatic stroke rates (11.1% vs. 7.7%; OR: 1.5; CI: 0.64-3.47, $p = 0.34$), perioperative strokes (6.2% vs. 2.1%; OR 3.13; 95% CI: 0.83-11.82, $p = 0.09$), or good functional outcomes at discharge (93% vs. 92.3%; OR 1.1; 95% CI: 0.45-2.69, $p = 0.82$).

Conclusion No significant differences in symptomatic stroke rates, perioperative strokes, or functional outcomes were observed between hypertensive and non-hypertensive Moyamoya patients. Appropriate management can lead to similar outcomes in both groups. Further prospective studies are required to validate these findings.

Keywords Moyamoya · HTN · Stroke · Multicenter

Introduction

Moyamoya disease (MMD) is a rare cerebrovascular disorder characterized by progressive steno-occlusive changes in the terminal portion of the internal carotid arteries and their main branches [23]. This pathological process leads to the formation of an abnormal vascular network at the base of the brain, which appears as a "puff of smoke" on angiography [23]. Although the etiology of MMD remains unclear, the

disease manifests in a bimodal distribution, primarily affecting children aged 5-14 and adults aged 45-54 [12].

Clinical presentations of MMD are diverse, including strokes, transient ischemic attacks (TIA), seizures, aphasia, headaches, cognitive impairments in children, dysarthria, and hemiparesis [20]. Diagnostic modalities for MMD include CT angiography (CTA), magnetic resonance imaging (MRI), and MR angiography (MRA), with conventional angiography remaining the gold standard for both diagnosis and surgical planning [4]. Management of MMD primarily involves revascularization procedures, which aim to prevent

Extended author information available on the last page of the article

stroke by enhancing cerebral blood flow in affected areas [1, 6, 15, 17].

It has been observed that a subset of MMD patients presents with renovascular hypertension, a condition associated with renal artery lesions [13, 19, 21]. The prevalence of renovascular hypertension in MMD patients is estimated to be around 2% [12, 27]. However, clinical observations suggest a higher prevalence of hypertension among MMD patients, raising concerns about its impact on disease outcomes [16].

Therefore, we aim to compare the clinical characteristics and outcomes of Moyamoya disease patients with and without hypertension using a multicenter, institutional, propensity score-matched analysis.

Methods

We conducted a multicenter, retrospective study in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines [5]. Institutional review board approval was obtained at all centers. No identifiable patient information was presented in the study and, thus, informed consent was not required.

Patient population

This study involved Moyamoya-affected hemispheres treated with surgical revascularization across 13 academic institutions predominantly in North America. Inclusion criteria were standardized across centers and included all patients with Moyamoya disease who underwent surgical revascularization treatment. Data were collected and analyzed on a per-hemisphere basis, categorizing hemispheres into hypertensive (above 139/89) and non-hypertensive (120/80 to 139/89) cohorts based on patient medical history. Hypertension was defined as a documented history of hypertension (systolic blood pressure >139 mmHg or diastolic blood pressure >89 mmHg) or the use of antihypertensive medications at the time of admission [26]. Patients with secondary causes of systemic hypertension, such as renal artery stenosis or endocrine disorders, were excluded from the analysis to focus on primary hypertension.

Data collected included patient demographics (age, gender, race, hypertension, diabetes mellitus, smoking status, sickle cell disease), presenting symptoms (TIA, stroke, subarachnoid hemorrhage (SAH), intraparenchymal hemorrhage, intraventricular hemorrhage (IVH), incidental finding), disease characteristics (laterality, Suzuki grade), procedural details (DR vs IR), complications (major, minor, hemorrhagic, ischemic, periprocedural),

follow-up (length of follow-up), and angiographic and functional outcomes (modified Rankin Score (mRS) and National Institute of Health Stroke Scale (NIHSS)).

Study endpoints

Study outcomes included major (ischemic or hemorrhagic with >4 change in NIHSS score) and minor (ischemic or hemorrhagic with <4 change in NIHSS score) symptomatic strokes (confirmed by imaging), good functional outcome (mRS 0-2) at discharge, NIHSS at discharge, length of hospital stay (days), perioperative strokes (including minor and major strokes confirmed by imaging), and follow-up strokes, categorized into ischemic and hemorrhagic after discharge. A stroke was defined by a new hypodensity on CT or a diffusion-weighted imaging hit on MRI not present on admission. A TIA was defined by a transient acute neurological deficit lasting less than 24 hours without radiographic evidence of stroke.

Statistical analysis

All statistical analyses were conducted using Stata (V.17.0; StataCorp). Baseline characteristics of hypertensive and non-hypertensive cohorts were compared using Pearson's chi-squared or Fisher's exact tests for categorical




Fig. 1 Flowchart shows the inclusion for patients in this study

Table 1 Comparison of baseline characteristics between unmatched patients with and without hypertension


	Total = 598	With hypertension = 292	Without hypertension = 306	P-value
Age, mean years (SD)	41.3 (14.6)	46.0 (12.5)	36.8 (15.1)	< 0.001
Male, n (%)	176/598 (29.4)	87/292 (29.7)	90/306(29.0)	0.84
Race, n (%)				
Caucasian	318/598 (53.1)	148/292 (50.6)	170/306 (55.5)	0.23
African-American	170/598 (28.4)	93/292(31.8)	77/306 (25.1)	0.07
Asian	70/598 (11.7)	33/292 (11.3)	37/306 (12.0)	0.80
Hispanic	27/598 (4.5)	10/292 (3.4)	17/306 (9.1)	0.24
other	13/598 (2.1)	8/292 (2.7)	5/306 (1.6)	0.40
Diabetes mellitus, n (%)	165/598 (27.5)	132/292 (45.2)	33/306 (10.7)	< 0.001
Smoker, n (%)	214/598 (35.7)	131/292 (48.8)	83/306 (27.1)	< 0.001
Family history of moyamoya, n (%)	10/598 (1.6)	6/292 (2.0)	4/306 (1.3)	0.53
Underlying disease, n (%)				
Sickle cell disease	33/598 (5.5)	10/292 (3.4)	23/306 (7.5)	0.03
Sickle cell trait	5/598 (0.8)	3/292 (1.3)	2/306 (0.6)	0.67
Neurofibromatosis	4/598 (0.67)	3/292 (1.0)	1/306 (0.3)	0.36
Procedure type, n (%)				
Indirect Revascularization	351/598 (58.7)	176/292 (60.2)	175/306 (57.1)	0.45
Direct Revascularization	305/598 (51.0)	155/292 (53.0)	150/306 (49.0)	0.32
Combined	58/598 (9.7)	39/292 (13.3)	19/306 (6.2)	0.004
Suzuki grade, n (%)				
I	24/598 (4.0)	12/289 (4.1)	12/303 (3.9)	1.0
II	71/598 (11.8)	31/292 (10.6)	40/306 (13.0)	0.37
III	181/598 (30.2)	95/292 (32.5)	86/306 (28.1)	0.23
IV	178/598 (29.7)	83/292 (28.4)	95/306 (31.0)	0.48
V	95/598 (15.8)	43/292 (14.7)	52/306 (16.9)	0.50
VI	41/598 (6.8)	24/292 (8.2)	17/306 (5.5)	0.25
Surgery side, n (%)				
Right hemisphere	306/598 (51.1)	148/292 (50.6)	158/306 (51.6)	0.81
Left hemisphere	292/598 (48.8)	144/292 (49.3)	148/306 (48.3)	0.81
Follow-up (months), median months (IQR)	17 (7-54)	16 (7-50)	17 (7-57)	0.64
mRS (0-2) on admission, n (%)	529/590 (89.6)	254/287 (88.5)	275/303 (90.7)	0.41
Incidental, n (%)	163/598 (27.2)	68/292 (23.2)	95/306 (31.0)	0.03
Stroke, n%				
Ischemic stroke	339/598 (56.6)	172/292 (58.9)	167/306 (54.5)	0.28
TIA	129/598 (21.5)	58/292 (19.8)	71/306 (23.2)	0.37
Intraventricular hemorrhage	15/598 (2.5)	10/292 (3.4)	5/306 (1.6)	0.19
Intracerebral hemorrhage	38/598 (6.3)	19/292 (6.5)	19/306 (6.2)	1.0
Subarachnoid hemorrhage	35/598 (5.8)	18/292 (6.1)	17/306 (5.5)	0.86

variables, and Student's t-test or Mann-Whitney U tests for continuous variables, as appropriate. Given the significant baseline differences between hypertensive and non-hypertensive patients—such as age, diabetes mellitus, and smoking status—we used propensity score matching (PSM) to control for these confounders [2]. PSM was performed in a 1:1 ratio without replacement, using a caliper of 0.2 standard deviations of the logit of the propensity score. Propensity scores were derived using a logistic regression model that accounted for all baseline characteristics.

The PSMATCH2 package for Stata was utilized for the propensity score derivation [14].

Outcome differences between hypertensive and non-hypertensive cohorts, both before and after matching, were assessed using univariable binary logistic and linear regression analyses, as appropriate. Results were reported as odds ratios (ORs) or beta coefficients with corresponding 95% confidence intervals (CIs). Fisher's exact test was used for comparing outcomes with zero frequencies. Statistical significance was set at $p < 0.05$, and all tests were two-tailed.

Fig. 2 Incidence of symptomatic stroke in Moyamoya disease patients with and without hypertension, before and after PSM



Because the number of missing data points was minimal, no imputation was performed to avoid introducing bias [11]. The analysis was conducted using available data only.

We also used a Cox Proportional Hazard Model to determine the effect of hypertension in both symptomatic stroke and follow-up stroke. The model was adjusted to age, smoking, Suzuki grade, procedure type, diabetes mellitus, underlying disease, surgery side, and incidental MMD.

Results

Baseline characteristics

A total of 598 patients were included, with 292 patients having hypertension and 306 patients without hypertension (Fig. 1). The mean age was significantly higher in the hypertension group (46 years, SD 12.5) compared to

Fig. 3 Perioperative stroke outcomes in Moyamoya disease patients with and without hypertension, before and after PSM




Table 2 Comparison of outcomes between unmatched patients with and without hypertension

	With hypertension = 292	Without hypertension = 306	Effect variable	Value (95% CI)	P-value
Symptomatic stroke, n (%)	41/252 (16.0)	19/263 (7.1)	OR	2.48 (1.39 to 4.40)	0.002
Symptomatic ischemic stroke, n (%)	37/255 (14.5)	16/263 (6.0)	OR	2.62 (1.41 to 4.48)	0.002
Symptomatic hemorrhagic stroke, n (%)	5/252 (1.9)	1/263 (0.3)	OR	5.30 (0.61 to 45.71)	0.12
Intraoperative complication, n (%)	31/292 (10.6)	21/306 (6.8)	OR	1.61 (0.90 to 2.87)	0.10
Perioperative stroke, n (%)	24/292 (8.2)	7/306 (2.2)	OR	3.82 (1.62 to 9.02)	0.002
Perioperative minor symptomatic stroke, n (%)	13/292 (4.4)	2/306 (0.6)	OR	7.08 (1.58 to 31.66)	0.01
Perioperative major symptomatic stroke, n (%)	11/292 (3.7)	3/306 (0.9)	OR	3.95 (1.09 to 14.31)	0.036
Good functional outcome at discharge, n (%)	264/290 (91.0)	281/303 (92.4)	OR	0.83 (0.47 to 1.50)	0.55
NIHSS at discharge, median (IQR)	0 (0-1)	0 (0-1)	Beta	-0.005 (-0.04 to 0.03)	0.76
Length of hospital stay, median (IQR)	4 (2-6)	3 (2-5)	Beta	0.02 (-0.00 to 0.06)	0.06
Follow-up stroke, n (%)	26/271 (9.5)	20/294 (6.8)	OR	1.45 (0.79 to 2.67)	0.22
Follow-up ischemic stroke, n (%)	23/292 (7.8)	18/306 (5.8)	OR	1.36 (0.72 to 2.59)	0.33
Follow-up hemorrhagic stroke, n (%)	3/292 (1.0)	2/306 (0.6)	OR	1.57 (0.26 to 9.51)	0.50

the non-hypertension group (36.8 years, SD 15.1) ($p < 0.001$). The gender distribution was similar between the two groups, with 29.7% of males in the hypertension group and 29% in the non-hypertension group ($p = 0.84$).

Comorbid conditions were more prevalent in the hypertension group, with higher rates of diabetes mellitus (45.2% vs. 10.7%, $p < 0.001$) and smoking (48.8% vs. 27.1%, $p < 0.001$). There was no significant difference in the family history of Moyamoya disease (2% vs. 1.3%, $p = 0.53$), but the prevalence of sickle cell disease was lower in the hypertension group (3.4% vs. 7.5%, $p = 0.03$). The rates of indirect revascularization were similar between the two groups (60.2% vs. 57.1%, $p = 0.45$). However, hypertensive moyamoya patients' group had a higher rate of combined revascularization compared to the non-hypertensive moyamoya patients' group (13.3% vs. 6.2%, $p = 0.004$) (Table 1).

Outcomes

The overall symptomatic stroke occurred more frequently in the hypertension group (16% vs. 7.1%; OR: 2.48; 95% CI: 1.39-4.40, $p = 0.002$) (Fig. 2). Symptomatic ischemic strokes were more common in the hypertension group (14.5% vs. 6%; OR: 2.62; CI: 1.41-4.48, $p = 0.002$). Moreover, the hypertension group had a higher rate of perioperative stroke (8.2% vs. 2.2%; OR: 3.82; CI: 1.62-9.02, $p = 0.002$) including minor symptomatic (4.4% vs. 0.6%; OR: 7.08; CI: 1.58-31.66, $p = 0.01$) and major symptomatic (3.7% vs. 0.9%; OR: 3.95; CI: 1.09-14.31, $p = 0.036$) compared to the non-hypertension group (Fig. 3).

Good functional outcome at discharge, measured by the mRS score, was similar between the groups (91% in hypertension vs. 92.4% in non-hypertension; OR 0.83; 95% CI: 0.47-1.50, $p = 0.55$). NIHSS scores at discharge were comparable

(median 0 in both groups, $p = 0.76$). Length of hospital stay was slightly longer in the hypertension group but did not reach statistical significance (median 4 days vs. 3 days, $p = 0.06$). Follow-up stroke rates were higher in the hypertension group but were not statistically significant (9.5% vs. 6.8%; OR 1.45; 95% CI: 0.79-2.67, $p = 0.22$) (Table 2).

Propensity score matching

PSM resulted in 143 matched pairs (Table 3) (Fig. 1). Although symptomatic stroke occurred more in the hypertensive group, it didn't reach statistical significance (11.1% vs. 7.7%; OR: 1.5; CI: 0.64-3.47, $p = 0.34$) (Fig. 2). Similarly, perioperative strokes were more common in the hypertension group but were not statistically significant (6.2% vs. 2.1%; OR 3.13; 95% CI: 0.83-11.82, $p = 0.09$) (Fig. 3). Good functional outcome at discharge was similar between the groups (93% in hypertension vs. 92.3% in non-hypertension; OR 1.1; 95% CI: 0.45-2.69, $p = 0.82$). NIHSS scores at discharge were comparable (median 0 in both groups, $p = 0.86$). Length of hospital stay was not significantly different (median 4 days vs. 3 days, $p = 0.91$). Follow-up stroke rates were similar between the groups (6.2% in hypertension vs. 5.5% in non-hypertension; OR 1.13; 95% CI: 0.42-3.02, $p = 0.8$) (Table 4).

Cox proportional hazard model

After adjusting the model to age, smoking, Suzuki grade, procedure type, diabetes mellitus, underlying disease, surgery side, and incidental MMD, there was no significant difference between the hypertension group and non-hypertension group in terms of symptomatic stroke (HR 1.33; 95% CI: 0.69-2.56, $p = 0.38$), and follow-up stroke (HR 0.90; 95% CI: 0.43-1.87, $p = 0.78$) (Supplementary Table 1).

Table 3 Comparison of baseline characteristics between matched patients with and without hypertension

	Total = 286	With hypertension = 143	Without hypertension = 143	P-value
Age, mean years (SD)	42.5 (14.4)	42.5 (12.2)	42.5 (12.7)	0.96
Male, n (%)	73/286 (25.5)	38/143 (26.5)	35/143 (24.4)	0.68
Race, n (%)				
Caucasian	166/286 (58.0)	48/143 (58.7)	82/143 (57.3)	0.90
African-American	82/286 (28.6)	41/143 (28.6)	41/143 (28.6)	1.00
Asian	21/286 (7.3)	10/143 (6.9)	11/143 (7.6)	1.00
Hispanic	10/286 (3.5)	5/143 (3.5)	5/143 (3.5)	1.00
other	7/286 (2.4)	3/143 (2.1)	4/143 (2.8)	1.00
Diabetes mellitus, n (%)	45/286 (15.7)	18/143 (12.5)	27/143 (18.8)	0.14
Smoker, n (%)	112/286 (39.1)	54/143 (37.7)	58/143 (40.5)	0.62
Family history of moyamoya, n (%)	7/286 (2.4)	3/143 (2.1)	4/143 (2.8)	1.00
Underlying disease, n (%)				
Sickle cell disease	14/286 (4.9)	8/143 (3.4)	6/143 (7.5)	0.78
Sickle cell trait	3/286 (1.0)	1/143 (0.7)	2/143 (1.4)	1.00
Neurofibromatosis	2/286 (0.7)	2/143 (1.4)	0/143 (0)	0.49
Procedure type, n (%)				
Indirect Revascularization	161/286 (56.2)	80/143 (55.9)	81/143 (56.6)	1.00
Direct Revascularization	147/286 (51.4)	71/143 (49.6)	76/143 (53.1)	0.55
Combined	22/286 (7.6)	8/143 (5.5)	14/143 (9.7)	0.26
Suzuki grade, n (%)				
I	12/286 (4.2)	6/143 (4.2)	6/143 (4.2)	1.00
II	28/286 (9.7)	16/143 (11.1)	12/143 (8.3)	0.55
III	90/286 (31.4)	42/143 (29.3)	48/143 (33.5)	0.44
IV	98/286 (34.2)	49/143 (34.2)	49/143 (34.2)	1.00
V	42/286 (14.6)	22/143 (15.3)	20/143 (13.9)	0.86
VI	17/286 (5.9)	8/143 (5.5)	9/143 (6.2)	1.00
Surgery side, n (%)				
Right hemisphere	153/286 (53.5)	67/143 (53.1)	66/143 (53.8)	0.90
Left hemisphere	133/286 (46.5)	67/143 (46.8)	66/143 (46.1)	0.90
Follow-up (months), median months (IQR)	16 (6-56)	21 (7-58)	15 (4-51)	0.27
mRS (0-2) on admission, n (%)	255/286 (89.1)	128/143 (89.5)	127/143 (88.8)	1.00
Incidental, n (%)	61/286 (21.3)	33/143 (23.0)	28/143 (19.5)	0.56
Stroke, n%				
Ischemic stroke	161/286 (56.2)	79/143 (55.2)	82/143 (57.3)	0.72
TIA	77/286 (21.3)	38/143 (23.0)	39/143 (19.5)	1.00
Intraventricular hemorrhage	6/286 (2.1)	2/143 (1.4)	4/143 (2.8)	0.68
Intracerebral hemorrhage	10/286 (3.5)	6/143 (4.2)	4/143 (2.8)	0.74
Subarachnoid hemorrhage	20/286 (6.9)	10/143 (6.9)	10/143 (6.9)	1.00

Discussion

In this study, hypertensive patients had a higher rate of symptomatic stroke, both ischemic and perioperative, compared to non-hypertensive patients. However, after propensity score matching, these differences did not reach statistical significance, indicating that confounding factors such as age, diabetes mellitus, and smoking status—more

prevalent in the hypertensive group—may have contributed to the increased stroke risk observed in the unmatched analysis. Additionally, our adjusted cox proportional analysis showed no significant difference between the two groups in symptomatic and follow-up stroke rates.

Hypertension is a well-established major risk factor for numerous cardiovascular disorders, including stroke, due to its profound adverse effects on cerebral vascular structure

Table 4 Comparison of outcomes between matched patients with and without hypertension

	With hypertension = 143	Without hypertension = 143	Effect variable	Value (95% CI)	P- value
Symptomatic stroke, n (%)	15/134 (11.1)	10/129 (7.7)	OR	1.5 (0.64 to 3.47)	0.34
Symptomatic ischemic stroke, n (%)	14/134 (10.4)	9/129 (6.9)	OR	1.55 (0.64 to 3.73)	0.32
Symptomatic hemorrhagic stroke, n (%)	1/134 (0.75)	1/129 (0.78)	OR	0.96 (0.05 to 15.55)	0.97
Intraoperative complication, n (%)	12/143 (8.3)	9/143 (6.2)	OR	1.36 (0.55 to 3.34)	0.49
Perioperative stroke, n (%)	9/143 (6.2)	3/143 (2.1)	OR	3.13 (0.83 to 11.82)	0.09
Perioperative minor symptomatic stroke, n (%)	6/143 (4.2)	1/143 (0.7)	OR	6.21 (0.73 to 52.33)	0.09
Perioperative major symptomatic stroke, n (%)	3/143 (2.1)	2/143 (1.4)	OR	1.51 (0.24 to 9.17)	0.65
Good functional outcome at discharge, n (%)	133/143 (93.0)	132/143 (92.3)	OR	1.10 (0.45 to 2.69)	0.82
NIHSS at discharge, median (IQR)	0 (0-0)	0 (0-0)	Beta	-0.004 (-0.05 to 0.04)	0.86
Length of hospital stay, median (IQR)	4 (2-4)	3 (2-5)	Beta	0.02 (-0.04 to 0.05)	0.91
Follow-up stroke, n (%)	9/143 (6.2)	8/143 (5.5)	OR	1.13 (0.42 to 3.02)	0.80
Follow-up ischemic stroke, n (%)	9/143 (6.2)	8/143 (5.5)	OR	1.13 (0.42 to 3.02)	0.80
Follow-up hemorrhagic stroke, n (%)	0/143 (0)	1/143 (0.7)	-	-	1.00

and function [22]. Previous studies have emphasized that hypertension accelerates atherogenesis and is associated with increased cardiovascular morbidity [3, 7, 8, 18].

A meta-analysis was done by Wei et al. [25] to investigate the risk factors for postoperative stroke in MMD patients. Hypertension was found not to be associated with increased risk of postoperative stroke. Our study aligns with these findings, where hypertension was found not to be associated with symptomatic stroke, perioperative stroke, follow-up stroke or functional outcomes.

In a study by Ma et al. which investigated the effect of hypertension on moyamoya patients, they reported a higher rate of unfavorable outcomes and postoperative complications in hypertensive moyamoya patients [16]. In contrast, our study showed no significant differences between hypertensive moyamoya patients and non-hypertensive moyamoya patients in postoperative complications or functional outcomes.

Another study by Wang et al. which analyzed the associations between clinical risk factors and long-term outcomes in moyamoya patients found that hypertension was positively associated with follow-up stroke [24]. However, our study still showed no significant differences between hypertensive moyamoya patients and non-hypertensive moyamoya patients regarding follow-up stroke (whether ischemic or hemorrhagic), both before and after PSM.

The differences between our study and those proposed by Ma et al. [16] and Wang et al. [24] can be explained by the fact that their studies were conducted exclusively on Chinese populations. Although Chinese populations may have lower rates of hypertension compared to the American population, this lower prevalence can lead to lower awareness and control, resulting in higher complication rates [9, 10, 28]. Our study included populations from different ethnicities, with

Caucasian populations being the most common. This suggests that treatment protocols and patient demographics can significantly impact outcomes in hypertensive Moyamoya patients.

This study has several limitations that should be considered. First, as a retrospective analysis, it is inherently subject to biases related to data collection and interpretation. Second, our focus was primarily on preoperative blood pressure values, without comprehensive monitoring of intraoperative and postoperative blood pressure variations, which could influence outcomes. Also, data on the severity of hypertension and the degree of its medical management were not uniformly available across all centers, limiting our ability to stratify these variables in our analysis. Additionally, the data were collected from multiple centers, leading to potential variability in clinical practices and patient management protocols. Third, the median follow-up period of 17 months is relatively short, which may limit the ability to capture long-term outcomes. Lastly, while propensity score matching was employed to balance baseline characteristics which provides a more accurate comparison between the groups, unmeasured confounders and reduction in statistical power may still affect the results.

Conclusion

In conclusion, hypertensive, and non-hypertensive patients with MMD showed no significant differences in symptomatic stroke rates, perioperative strokes, or functional outcomes. Proper management can lead to comparable recovery in both groups. Further research is needed to optimize treatment strategies for hypertensive Moyamoya patients.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s00701-024-06254-0>.

Acknowledgments None.

Author contributions B.M., J.M.R., H.A., E.A., K.E.N., C.J.C., R.J., H.S., J.A.G., A.A.D., A.B., M.K., C.S.O., A.J.T., A.M., A.S., G.M.C., R.A.H., G.P., A.M.S., A.J.P., D.M.H., M.G., J.W., S.M.N., K.B., M.M.S., J.B., A.Z., C.M., B.M.H., R.L., R.D., R.A., G.S.S., A.A., A.M., N.A.H., S.I.T., M.R.G., R.H.R., P.J. contributed to the conception and design of the work.

B.M., J.M.R., H.A., E.A., K.E.N., C.J.C., R.J., H.S., J.A.G., A.A.D., A.B., M.K., C.S.O., A.J.T., A.M., A.S., G.M.C., R.A.H., G.P., A.M.S., A.J.P., D.M.H., M.G., J.W., S.M.N., K.B., M.M.S., J.B., A.Z., C.M., B.M.H., R.L., R.D., R.A., G.S.S., A.A., A.M., N.A.H., S.I.T., M.R.G., R.H.R., P.J. were involved in the acquisition of data, and data analysis and interpretation.

B.M., J.M.R., H.A., E.A., K.E.N., C.J.C., R.J., H.S., J.A.G., A.A.D., A.B., M.K., C.S.O., A.J.T., A.M., A.S., G.M.C., R.A.H., G.P., A.M.S., A.J.P., D.M.H., M.G., J.W., S.M.N., K.B., M.M.S., J.B., A.Z., C.M., B.M.H., R.L., R.D., R.A., G.S.S., A.A., A.M., N.A.H., S.I.T., M.R.G., R.H.R., P.J. drafted the work and revised it critically for important intellectual content.

All authors gave final approval of the version to be published and agree to be accountable for all aspects of the manuscript.

Funding This research received no grant from any funding agency in public, commercial, or not-for-profit sectors.

Data availability Data can be provided on reasonable request from authors.

Declarations

Ethical approval All procedures performed in the studies involving human participants were per the Institutional Review Board (IRB) ethical standards and national research committee and the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent The study protocol was reviewed and approved by the Institutional Review Board. Following institutional guidelines, all protected health information was removed, and individual patient consent was not required in the analysis of the case series.

Competing interests Dr. Jabbour is a consultant for Medtronic, Microvention, Balt and Cerus Endovascular. Dr. Tjoumakaris is a consultant for Microvention. Dr. Gooch is a consultant for Stryker. Dr. Spiotta is a consultant for Terumo, Stryker, Penumbra, RapidAI, Cerenovus. Dr. Patel is a consultant for Microvention and Medtronic. Dr. Du is a consultant for grand rounds. Dr. Burkhardt is a consultant for Longeviti Neuro solutions, Q-Apel Medical, Stryker. Dr. Hanel is a consultant for Medtronic, Balt, Stryker, Q'Apel Medical, Inc, Codman Neuro (J&J), Cerenovus, Microvention, Imperative Care, Inc, Phenox, Inc, Rapid Medical. Dr. Siddiqui is a consultant for Amnis Therapeutics, Apellis Pharmaceuticals, Inc., Boston Scientific, Canon Medical Systems USA, Inc., Cardinal Health 200, LLC, Cerebrotech Medical Systems, Inc., Cerenovus, Cerevatech Medical, Inc., Cordis, Corindus, Inc., Endostream Medical, Ltd, Imperative Care, InspireMD, Ltd., Integra, IRRAS AB, Medtronic, Microvention, Minnetronix Neuro, Inc., Peijia Medical, Penumbra, Q'Apel Medical, Inc., Rapid Medical, Serenity Medical, Inc., Silk Road Medical, StimMed, LLC, Stryker Neurovascular, Three Rivers Medical, Inc., VasSol, Viz.ai, Inc. The other authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long

as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Amlie-Lefond C, Ellenbogen RG (2015) Factors associated with the presentation of moyamoya in childhood. *J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc* 24(6):1204–1210. <https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.01.018>
2. Amoah J, Stuart EA, Cosgrove SE et al (2020) Comparing propensity score methods versus traditional regression analysis for the evaluation of observational data: a case study evaluating the treatment of gram-negative bloodstream infections. *Clin Infect Dis Off Publ Infect Dis Soc Am* 71(9):e497–e505. <https://doi.org/10.1093/cid/ciaa169>
3. Anim JI, Kofi AD (1989) Hypertension, cerebral vascular changes and stroke in Ghana: cerebral atherosclerosis and stroke. *East Afr Med J* 66(7):468–475
4. Chiu D, Shedden P, Bratina P, Grotta JC (1998) Clinical features of moyamoya disease in the United States. *Stroke* 29(7):1347–1351. <https://doi.org/10.1161/01.str.29.7.1347>
5. Cuschieri S (2019) The STROBE guidelines. *Saudi J Anaesth* 13(Suppl 1):S31–S34. https://doi.org/10.4103/sja.SJA_543_18
6. El Naamani K, Chen CJ, Jabre R et al (2024) Direct versus indirect revascularization for moyamoya: a large multicenter study. *J Neurol Neurosurg Psychiatry* 95(3):256–263. <https://doi.org/10.1136/jnnp-2022-329176>
7. Ellenga Mbolla BF, Gombet TR, Atipo-Ibara BI, Etiele F, Kimbally-Kaky G (2012) Impact of severe hypertension in acute heart failure in Brazzaville (Congo). *Med Sante Trop* 22(1):98–99. <https://doi.org/10.1684/mst.2012.0017>
8. Ewen E, Zhang Z, Kolm P et al (2009) The risk of cardiovascular events in primary care patients following an episode of severe hypertension. *J Clin Hypertens Greenwich Conn* 11(4):175–182. <https://doi.org/10.1111/j.1751-7176.2009.00097.x>
9. FastStats. April 29, 2024. <https://www.cdc.gov/nchs/fastats/hypertension.htm>. Accessed 22 June 2024
10. Hypertension China 2023 country profile. <https://www.who.int/publications/m/item/hypertension-chn-2023-country-profile>. Accessed 22 June 2024
11. Imputing Missing Data with R; MICE package | DataScience+. <https://datascienceplus.com/imputing-missing-data-with-r-mice-package/>. Accessed 10 Aug 2024
12. Kim JS (2016) Moyamoya disease: epidemiology, clinical features, and diagnosis. *J Stroke* 18(1):2–11. <https://doi.org/10.5853/jos.2015.01627>
13. Kuwayama F, Hamasaki Y, Shinagawa T et al (2001) Moyamoya disease complicated with renal artery stenosis and nephrotic syndrome: reversal of nephrotic syndrome after nephrectomy. *J Pediatr* 138(3):418–420. <https://doi.org/10.1067/mpd.2001.111330>
14. Leuven E, Sianesi B PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing. *Stat Softw Compon*. Published online February 1, 2018. <https://ideas.repec.org/c/boc/bocode/s432001.html>. Accessed 21 June 2024

15. Liu X, Zhang D, Shuo W, Zhao Y, Wang R, Zhao J (2013) Long term outcome after conservative and surgical treatment of haemorrhagic moyamoya disease. *J Neurol Neurosurg Psychiatry* 84(3):258–265. <https://doi.org/10.1136/jnnp-2012-302236>
16. Ma Y, Zhao M, Deng X et al (2020) Comparison of clinical outcomes and characteristics between patients with and without hypertension in moyamoya disease. *J Clin Neurosci Off J Neurosurg Soc Australas* 75:163–167. <https://doi.org/10.1016/j.jocn.2019.12.016>
17. Macyszyn L, Attiah M, Ma TS et al (2017) Direct versus indirect revascularization procedures for moyamoya disease: a comparative effectiveness study. *J Neurosurg* 126(5):1523–1529. <https://doi.org/10.3171/2015.8.JNS15504>
18. Mourad JJ (2013) Severe hypertension: definition and patients profiles. *Rev Prat* 63(5):672–676
19. van der Vliet JA, Zeilstra DJ, Van Roye SF, Merx JL, Assmann KJ (1994) Renal artery stenosis in moyamoya syndrome. *J Cardiovasc Surg (Torino)* 35(5):441–443
20. Scott RM, Smith ER (2009) Moyamoya disease and moyamoya syndrome. *N Engl J Med* 360(12):1226–1237. <https://doi.org/10.1056/NEJMra0804622>
21. Shang S, Zhou D, Ya J et al (2020) Progress in moyamoya disease. *Neurosurg Rev* 43(2):371–382. <https://doi.org/10.1007/s10143-018-0994-5>
22. Sobey CG, Faraci FM (2001) Novel mechanisms contributing to cerebral vascular dysfunction during chronic hypertension. *Curr Hypertens Rep* 3(6):517–523. <https://doi.org/10.1007/s11906-001-0015-9>
23. Suzuki J, Takaku A (1969) Cerebrovascular, “moyamoya” disease. Disease showing abnormal net-like vessels in base of brain. *Arch Neurol* 20(3):288–299. <https://doi.org/10.1001/archneur.1969.00480090076012>
24. Wang X, Zhang Z, Wang Y et al (2021) Clinical and genetic risk factors of long-term outcomes after encephaloduroarteriosynangiosis in moyamoya disease in China. *J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc* 30(7):105847. <https://doi.org/10.1016/j.jstrokecerebrovasdis.2021.105847>
25. Wei W, Chen X, Yu J, Li XQ (2019) Risk factors for postoperative stroke in adults patients with moyamoya disease: a systematic review with meta-analysis. *BMC Neurol* 19(1):98. <https://doi.org/10.1186/s12883-019-1327-1>
26. Whelton PK, Carey RM, Aronow WS et al (2018) ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertens Dallas Tex* 71(6):1269–1324. <https://doi.org/10.1161/HYP.0000000000000066>
27. Yamada I, Himeno Y, Matsushima Y, Shibuya H (2000) Renal artery lesions in patients with moyamoya disease: angiographic findings. *Stroke* 31(3):733–737. <https://doi.org/10.1161/01.str.31.3.733>
28. Zhang M, Shi Y, Zhou B et al (2023) Prevalence, awareness, treatment, and control of hypertension in China, 2004–18: findings from six rounds of a national survey. *BMJ* 380:e071952. <https://doi.org/10.1136/bmj-2022-071952>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Basel Musmar¹ · Joanna M. Roy¹ · Hammam Abdalrazeq¹ · Elias Atallah¹ · Kareem El Naamani² · Ching-Jen Chen³ · Roland Jabre¹ · Hassan Saad⁴ · Jonathan A. Grossberg⁴ · Adam A. Dmytriw^{5,6} · Aman B. Patel⁶ · Mirhojjat Khorasanizadeh⁷ · Christopher S Ogilvy⁷ · Ajith J. Thomas⁸ · Andre Monteiro⁹ · Adnan Siddiqui⁹ · Gustavo M. Cortez¹⁰ · Ricardo A. Hanel¹⁰ · Guilherme Porto¹¹ · Alejandro M. Spiotta¹¹ · Anthony J. Piscopo¹² · David M. Hasan¹³ · Mohammad Ghorbani¹⁴ · Joshua Weinberg¹⁵ · Shahid M. Nimjee¹⁵ · Kimon Bekelis¹⁶ · Mohamed M. Salem¹⁷ · Jan-Karl Burkhardt¹⁷ · Akli Zetchi^{18,19} · Charles Matouk^{18,19} · Brian M. Howard⁴ · Rosalind Lai⁶ · Rose Du⁶ · Rawad Abbas¹ · Georgios S Sioutas¹ · Abdelaziz Amlay¹ · Alfredo Munoz¹ · Nabeel A. Herial¹ · Stavropoula I. Tjoumakaris¹ · Michael Reid Gooch¹ · Robert H. Rosenwasser¹ · Pascal Jabbour¹

✉ Pascal Jabbour
pascal.jabbour@jefferson.edu

¹ Department of Neurological Surgery, Thomas Jefferson University Hospital, 901 Walnut street 3rd Floor, Philadelphia, Pennsylvania 19107, USA

² Department of Neurosurgery, University of Arizona college of medicine, Tucson, Arizona, USA

³ Department of Neurosurgery, The University of Texas Health Science Center, Houston, TX, USA

⁴ Department of Neurosurgery, Emory University, Atlanta, Georgia, USA

⁵ Department of Medical Imaging, University of Toronto Faculty of Medicine, Toronto, Ontario, Canada

⁶ Neuroendovascular Program, Massachusetts General Hospital & Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

⁷ Department of Neurosurgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA

⁸ Department of Neurological Surgery, Cooper University Health Care, Cooper Medical School of Rowan University, Camden, NJ, USA

⁹ Department of Neurosurgery, University of New York at Buffalo, Buffalo, NY, USA

¹⁰ Lyerly Neurosurgery, Baptist Health System, Jacksonville, FL, USA

¹¹ Department of Neurosurgery and Neuroendovascular Surgery, Medical University of South Carolina, Charleston, SC, USA

¹² Department of Neurosurgery, University of Iowa Hospital and Clinics, Iowa City, IA, USA

¹³ Department of Neurosurgery, Duke University, Durham, NC, USA

¹⁴ Department of Neurosurgery, Firoozgar Hospital, Tehran, Iran

¹⁵ Department of Neurosurgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA

¹⁶ Good Samaritan Hospital Medical Center, Babylon, NY, USA

¹⁷ Department of Neurosurgery, Hospital of the University of Pennsylvania, Penn Medicine, Philadelphia, PA, USA

¹⁸ Department of Neurosurgery, Yale University, New Haven, CT, USA

¹⁹ Department of Neurosurgery and of Radiology and Biomedical Imaging, Yale University, New Haven, CT, USA